参芪六味汤治疗脾虚痰浊型血脂异常的临床疗效研究

发布时间：2018-10-23 13:33

【摘要】：目的:观察参芪六味汤联合西药治疗脾虚痰浊型血脂异常的临床疗效。方法:按照随机数字表法将60例年龄在60岁至75岁的脾虚痰浊型血脂异常患者分为治疗组与对照组各30例。治疗组每日服用剂量为20mg阿托伐他汀钙片联合参芪六味汤一剂口服,疗程为8周;对照组每天只服用剂量为20mg阿托伐他汀钙片,疗程为8周。分别测定治疗前、治疗4周、治疗8周时总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平;检测治疗前后肝肾功能及肌酸激酶,记录治疗前后中医证候积分。结果:两组治疗前血脂指标比较差异无统计学意义(P0.05),两组基线一致,血脂指标具有可比性。两组治疗4周与同组治疗前比较,差异有统计学意义(P0.05),说明4周时两组都可以降低TC、TG、LDL-C以及升高HDL-C,治疗4周两组间比较无统计学意义(P0.05),说明两组治疗疗效相当,同时也说明中药联合西药组在治疗4周时中药无作用或者作用微小。两组治疗4周与8周比较差异有统计学意义(P0.05),说明两组治疗8周时比治疗4周能降低TC、TG、LDL-C以及升高HDL-C,治疗8周两组间比较差异有统计学意义(P0.05),说明中药联合西药组在治疗8周时疗效比单纯西药组更优胜。两组治疗前的中医症候积分比较差异无统计学意义(P0.05);治疗组治疗8周后与同组治疗前比较,中医症候积分差异有统计学意义(P0.05);对照组治疗8周后与同组治疗前比较,中医症候积分差异无统计学意义(P0.05);肝、肾功能及血清肌酸激酶各项指标,其相关统计学结果显示两组患者治疗前后各指标均无差异(P0.05)。结论:参芪六味汤可降低中医症候积分以及明显改善血脂水平,提高脾虚痰浊型血脂异常临床疗效,且优于单纯西药组,临床安全性好,值得临床进一步研究。
[Abstract]:Objective: to observe the clinical effect of Shenqi Liuwei decoction combined with western medicine in treating dyslipidemia of spleen deficiency and phlegm turbid type. Methods: 60 patients with spleen deficiency and phlegm turbid dyslipidemia were randomly divided into treatment group (n = 30) and control group (n = 30). The treatment group was treated with 20mg Atto vastatin calcium tablets combined with Shenqi Liuwei decoction daily for 8 weeks, while the control group only took 20mg Atto vastatin calcium tablets daily for 8 weeks. The levels of (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), liver and kidney function and creatine kinase were measured before and after treatment. Record the integral of TCM syndrome before and after treatment. Results: there was no significant difference in blood lipid index between the two groups before treatment (P0.05). The baseline of the two groups was the same and the blood lipid index was comparable. The difference between the two groups before treatment was statistically significant (P0.05), which indicated that both groups could reduce TC,TG,LDL-C and increase HDL-C, at 4 weeks after treatment (P0.05), which indicated that the two groups had the same curative effect, but no significant difference between the two groups before treatment (P0.05), which indicated that there was no significant difference between the two groups after 4 weeks of treatment (P0.05). At the same time, it also showed that Chinese medicine combined with western medicine had no effect or little effect after 4 weeks of treatment. The difference between the two groups at 4 weeks and 8 weeks was statistically significant (P0.05), which indicated that the two groups could reduce TC,TG,LDL-C at 8 weeks and increase HDL-C, in 8 weeks (P0.05), which indicated that the Chinese medicine combined with western medicine had a significant difference between the two groups (P0.05). After 8 weeks of treatment, the therapeutic effect was better than that of western medicine alone. There was no significant difference in TCM symptom score between the two groups before treatment (P0.05); in the treatment group after 8 weeks of treatment compared with the same group before treatment, TCM symptom score difference was statistically significant (P0.05); in the control group after 8 weeks of treatment and the same group before treatment comparison, There was no significant difference in TCM symptom score (P0.05); liver, kidney function and serum creatine kinase indexes, the related statistical results showed that the two groups of patients before and after treatment did not differ in each index (P0.05). Conclusion: Shenqi Liuwei decoction can reduce the symptom score of TCM and improve the level of blood lipids obviously, and improve the clinical effect of abnormal blood lipids of spleen deficiency and phlegm turbid type, and it is superior to the western medicine group, the clinical safety is good, and it is worthy of further clinical study.
【学位授予单位】：广西中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】